PMC:7283670 / 62679-62976 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T582","span":{"begin":163,"end":167},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"}],"text":"Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T159","span":{"begin":14,"end":24},"obj":"Chemical"},{"id":"T160","span":{"begin":265,"end":271},"obj":"Chemical"}],"attributes":[{"id":"A159","pred":"chebi_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A160","pred":"chebi_id","subj":"T160","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"}],"text":"Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14"}

{"project":"LitCovid-sentences","denotations":[{"id":"T638","span":{"begin":0,"end":297},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T221","span":{"begin":255,"end":260},"obj":"Phenotype"}],"attributes":[{"id":"A221","pred":"hp_id","subj":"T221","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1890","span":{"begin":34,"end":46},"obj":"Species"},{"id":"1891","span":{"begin":220,"end":232},"obj":"Species"},{"id":"2063","span":{"begin":14,"end":24},"obj":"Chemical"},{"id":"2128","span":{"begin":255,"end":260},"obj":"Disease"}],"attributes":[{"id":"A1890","pred":"tao:has_database_id","subj":"1890","obj":"Tax:9606"},{"id":"A1891","pred":"tao:has_database_id","subj":"1891","obj":"Tax:9606"},{"id":"A2063","pred":"tao:has_database_id","subj":"2063","obj":"MESH:C000606551"},{"id":"A2128","pred":"tao:has_database_id","subj":"2128","obj":"MESH:D005334"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14"}